Codexis’ (CDXS) “Overweight” Rating Reiterated at Stephens

Codexis (NASDAQ:CDXS – Get Free Report)‘s stock had its “overweight” rating reiterated by research analysts at Stephens in a note issued to investors on Monday, Benzinga reports. They presently have a $5.00 target price on the biotechnology company’s stock. Stephens‘s target price indicates a potential upside of 331.03% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings raised shares of Codexis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 23rd. Benchmark reissued a “hold” rating on shares of Codexis in a report on Thursday, August 20th. Piper Sandler decreased their price objective on shares of Codexis from $9.00 to $8.00 and set an “overweight” rating on the stock in a research report on Monday, August 17th. Finally, Wall Street Zen upgraded shares of Codexis from a “sell” rating to a “hold” rating in a research report on Saturday. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $6.00.

View Our Latest Analysis on CDXS

Codexis Stock Performance

Shares of CDXS stock opened at $1.16 on Monday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 2.99 and a current ratio of 3.06. Codexis has a fifty-two week low of $0.90 and a fifty-two week high of $2.98. The stock has a 50 day moving average price of $1.29 and a two-hundred day moving average price of $1.78. The company has a market capitalization of $127.03 million, a P/E ratio of -5.80 and a beta of 2.38.

Codexis (NASDAQ:CDXS – Get Free Report) last issued its earnings results on Thursday, November 12th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.02. Codexis had a negative net margin of 21.77% and a negative return on equity of 45.54%. The firm had revenue of $19.26 million for the quarter, compared to analysts’ expectations of $18.72 million. Analysts expect that Codexis will post -0.37 earnings per share for the current year.

Hedge Funds Weigh In On Codexis

Several hedge funds have recently made changes to their positions in CDXS. BlackRock Inc. purchased a new stake in shares of Codexis in the 2nd quarter worth about $16,463,000. Nantahala Capital Management LLC bought a new stake in shares of Codexis during the 2nd quarter valued at about $8,189,365. Man Group plc bought a new stake in shares of Codexis during the 2nd quarter valued at about $1,278,000. Assenagon Asset Management S.A. increased its position in shares of Codexis by 70.2% during the second quarter. Assenagon Asset Management S.A. now owns 1,278,206 shares of the biotechnology company’s stock valued at $2,889,000 after buying an additional 527,036 shares during the period. Finally, Stonepine Capital Management LLC purchased a new position in shares of Codexis during the second quarter valued at about $247,836. 78.54% of the stock is owned by hedge funds and other institutional investors.

About Codexis

(Get Free Report)

Codexis, Inc. is a biotechnology company that develops engineered enzymes for pharmaceutical and other manufacturing applications. Founded in 2002 and based in Redwood City, California, the company uses its protein-engineering platform, CodeEvolver, to design enzymes with properties suited to specific production processes. Codexis supplies enzymes and related development services for the manufacture of small-molecule drugs and other products. It also develops its ECO Synthesis platform, which uses enzymes to support the production of oligonucleotide therapeutics, including RNA-based medicines.

Further Reading

Analyst Recommendations for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.